Tscan Therapeutics Net Tangible Assets

Tscan Therapeutics (TCRX) currently reports a net tangible assets of $69M as of June 2026. That compares with $180M in the prior-year period — down 60.9% year over year. Use the charts on this page to explore Tscan Therapeutics's net tangible assets history and peer comparisons.

Tscan Therapeutics's net tangible assets decreased from $180M to $69M — a 60.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tscan Therapeutics reported $69M in net tangible assets as of June 2026. That compares with $180M in the prior-year period — down 60.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $69M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Tscan Therapeutics, and consider following TCRX for alerts when major investors trade the stock.

Tscan Therapeutics is classified in the Healthcare sector. On net tangible assets, it currently shows $69M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TCRX with unrelated industries.